The first eligible drugs treat diabetes, blood clots, blood cancers, arthritis, and heart disease — and accounted for about $50 billion in spending from June 2022 to May 2023.
We still need you!
With your help, we've gotten a lot done — but we're not finished yet!
Help keep the momentum going by rejoining our member community today.
